Bruce Cozadd, CEO of Jazz Pharmaceuticals. Photograph: Dara Mac Dónaill

It’s a stock market darling, delivering recurring double-digit revenue growth, a growing pipeline, regularly listed among prime M&A targets in the(...)

Profector’s patent-protected electrospraying and electrospinning technology is aimed at research scientists in academic institutions, life sciences companies and government agencies

  Adapt Pharma, the latest venture of serial pharmaceuticals entrepreneur Séamus Mulligan, has invested in a high-tech medical devices bus(...)

Jazz Pharma is based in Ireland following its $500 million acquisition of Azur Pharma in 2012

Jazz Pharma, the specialty drug group based in Ireland following its $500 million acquisition of Azur Pharma in 2012, has reported strong growth in it(...)

Séamus Mulligan  co-founded Dublin-based Adapt with fellow serial pharmaceutical entrepreneurs David Brabazon and Eunan Maguire

Entrepreneur Séamus Mulligan has cashed in shares worth $86 million (€62 million) in Jazz Pharmaceuticals which will entirely be used to fund a new(...)

An Taoiseach Enda Kenny and Bruce Cozadd, chairman and chief executive of Jazz Pharmaceuticals plc, in  Monksland, Athlone, Co Roscommon, on Monday.

Jazz Pharmaceuticals is investing €50 million on a new manufacturing plant outside Athlone, Co Roscommon, that will create 50 high-skilled full-time j(...)

Jazz Pharmaceuticals, the Dublin-based maker of the narcolepsy treatment Xyrem, is buying Italian rare disease drug developer Gentium in a $1 billion (...)

A US bidder swoops for Elan triggering speculation that more Irish-domiciled drug companies may find themselves in the crosshairs of acquisitive forei(...)

Dublin-based Jazz Pharmaceuticals is seeking $757.2 million in loans to refinance debt, according to a person with knowledge of the transaction. Barcl(...)

Investors in pharmaceuticals businesses are a nervous bunch as Bruce Cozadd and his team at Dublin-based Jazz Pharmaceuticals discovered this w(...)